Negative side effects of opioids could be coming from users' own immune systems (video)

August 17, 2020

WASHINGTON, Aug. 17, 2020 -- In addition to possibly developing opioid use disorder, those who take opioids long term, including patients who have been prescribed the drugs for pain relief, can develop chronic inflammation and heightened pain sensitivity. Scientists now report in a pilot study that some of those side effects might be influenced by the body's own immune system, which can make antibodies against the drugs.

The researchers will present their results today at the American Chemical Society (ACS) Fall 2020 Virtual Meeting & Expo. ACS is holding the meeting through Thursday. It features more than 6,000 presentations on a wide range of science topics.

A brand-new video on the research is available at http://www.acs.org/fall2020-opioids.

"Extrapolating from previous work on opioid vaccines, we started thinking that the patient's own immune system could be responsible for some of the negative effects of long-term opioid use," says Cody J. Wenthur, Pharm.D., Ph.D., who led the study. "We thought the body could be mounting an immune response and making antibodies against the drugs."

The researchers, who are at the University of Wisconsin-Madison School of Pharmacy, Scripps Research and Scripps Clinic, realized that one issue with this hypothesis is that commonly prescribed opioids for back pain, such as hydrocodone or oxycodone, are not large enough molecules for the immune system to recognize as antigens. From their past studies, however, they knew that an immune response could be triggered if something larger were bound to the drugs. This could happen in the body when a protein in the bloodstream reacts with the opioid to create a larger molecule in a process called haptenization.

To find out whether long-term opioid users produced antibodies against the drugs, the team performed an enzyme-linked immunosorbent assay (ELISA). Blood samples were obtained from 19 patients who used either hydrocodone or oxycodone for chronic back pain and from three control patients who used over-the-counter remedies (OTCs) or non-pharmacologic approaches. Jillian Kyzer, Ph.D., a postdoc in Wenthur's lab, along with Hyeri Park, Ph.D., a postdoc in the laboratory of Kim Janda, Ph.D., developed new techniques to synthesize hydrocodone and oxycodone haptens, linking them with a common blood protein to form bioconjugates. These bioconjugates were then coated on the surface of ELISA plates, and the patients' blood samples were added. If antibodies against the haptens were present in the patients' blood, they would stick to the surface of the plate and would be detected by another antibody that binds and creates a colorful dye through an enzyme-linked reaction.

Anti-opioid antibodies were found in the plasma of 10 people who regularly took prescription opioids for chronic lower back pain and almost none were found in those who used OTCs. The larger the dose of opioid, the larger the antibody response. "This was surprising," Kyzer says. "We saw antibody responses in people who were taking large doses for as little as 6 months."

The scientists are now working on isolating the key opioid antigenic intermediates in the body that prompt the generation of antibodies. One possibility is that the intermediates are modified proteins known as advanced glycation end products (AGEs), which could form when hydrocodone or oxycodone metabolites react with a carbohydrate. AGEs have been implicated in diseases such as atherosclerosis, cancer and Alzheimer's disease, and they might help explain chronic inflammation in long-term opioid users. The researchers have observed preliminary signals of hydrocodone-associated AGE formation under conditions relevant to those found in the human body, and they are planning to validate these results soon.

Wenthur says the findings support undertaking a broader study to determine the prevalence of antibodies in people based on race, age and sex. "The research could also be helpful in identifying efficacy biomarkers for opioid vaccines that are entering clinical trials," Kyzer says. "If our findings hold up in subsequent research, you would expect individuals with higher levels of these antibodies to be poor candidates for anti-opioid vaccine therapy."
-end-
A press conference on this topic will be held Monday, Aug. 17, at 9 a.m. Eastern time online at http://www.acs.org/fall2020pressconferences.

The researchers acknowledge support and funding from the ALSAM Foundation, as well as funds from the University of Wisconsin-Madison School of Pharmacy and the University of Wisconsin-Madison Office of the Vice Chancellor for Research and Graduate Education.

The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS' mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people. The Society is a global leader in providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a specialist in scientific information solutions (including SciFinder® and STN®), its CAS division powers global research, discovery and innovation. ACS' main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive press releases from the American Chemical Society, contact newsroom@acs.org.

Note to journalists: Please report that this research was presented at a meeting of the American Chemical Society.

Follow us: Twitter | Facebook

Title

Investigation of the mechanism of immunologic response to chronic opioid use

Abstract

Long-term opioid use has not been shown to be more effective than NSAIDS for chronic pain, however one study showed that 61% of patients with chronic back pain were prescribed opioids at least once in the previous year, and 31% of patients were categorized as long-term opiate users. In addition to the risk of developing opioid use disorder (OUD), long-term opioid use has been shown to cause chronic inflammation and hyperalgesia, suggesting that opioids may induce an immune response upon chronic use.

To investigate this hypothesis, plasma samples were obtained from individuals with chronic back pian who had been prescribed opioids as well as negative controls. The plasma samples were analyzed by enzyme-linked immunosorbent assay (ELISA), screening against bovine serum albumin (BSA) conjugated to either oxycodone or hydrocodone to quantify the levels of opioid-specific antibodies in the samples Varying levels of antibodies were found, and we thus investigated the potential mechanism by which these antibodies were produced. As other drugs containing secondary amines have been shown to form advanced glycation endproducts (AGEs) which can generate self-reactive antibodies, we hypothesized that norhydrocodone and noroxycodone would as well. We investigated the potential for norhydrocodone to form AGEs through monitoring in vitro formation of reactive intermediates.

American Chemical Society

Related Science Articles from Brightsurf:

75 science societies urge the education department to base Title IX sexual harassment regulations on evidence and science
The American Educational Research Association (AERA) and the American Association for the Advancement of Science (AAAS) today led 75 scientific societies in submitting comments on the US Department of Education's proposed changes to Title IX regulations.

Science/Science Careers' survey ranks top biotech, biopharma, and pharma employers
The Science and Science Careers' 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Science in the palm of your hand: How citizen science transforms passive learners
Citizen science projects can engage even children who previously were not interested in science.

Applied science may yield more translational research publications than basic science
While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May 9, 2018 in the open-access journal PLOS ONE by Xueying Han from the Science and Technology Policy Institute, USA, and colleagues.

Prominent academics, including Salk's Thomas Albright, call for more science in forensic science
Six scientists who recently served on the National Commission on Forensic Science are calling on the scientific community at large to advocate for increased research and financial support of forensic science as well as the introduction of empirical testing requirements to ensure the validity of outcomes.

World Science Forum 2017 Jordan issues Science for Peace Declaration
On behalf of the coordinating organizations responsible for delivering the World Science Forum Jordan, the concluding Science for Peace Declaration issued at the Dead Sea represents a global call for action to science and society to build a future that promises greater equality, security and opportunity for all, and in which science plays an increasingly prominent role as an enabler of fair and sustainable development.

PETA science group promotes animal-free science at society of toxicology conference
The PETA International Science Consortium Ltd. is presenting two posters on animal-free methods for testing inhalation toxicity at the 56th annual Society of Toxicology (SOT) meeting March 12 to 16, 2017, in Baltimore, Maryland.

Citizen Science in the Digital Age: Rhetoric, Science and Public Engagement
James Wynn's timely investigation highlights scientific studies grounded in publicly gathered data and probes the rhetoric these studies employ.

Science/Science Careers' survey ranks top biotech, pharma, and biopharma employers
The Science and Science Careers' 2016 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Three natural science professors win TJ Park Science Fellowship
Professor Jung-Min Kee (Department of Chemistry, UNIST), Professor Kyudong Choi (Department of Mathematical Sciences, UNIST), and Professor Kwanpyo Kim (Department of Physics, UNIST) are the recipients of the Cheong-Am (TJ Park) Science Fellowship of the year 2016.

Read More: Science News and Science Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.